Articles & Research from Venn Life Sciences

How our Drug Development Plan can help you get funding

An academic spin-off biotech with only a handful of people on board was preparing for their new biological entity for clinical development. For the drug product itself, they needed to a CMC process and conduct necessary nonclinical studies. To make all these happen, they needed...

10 Essential Considerations for Successful Clinical Development of ATMPs

The clinical development of Advanced Therapy Medicinal Products (ATMPs) can be a daunting task, but partnering with a team of experts can pave the way for success. In this blog, we highlight ten key considerations that can make the development process less risky and more...

Accelerating Drug Development from lab to patient, fast & efficiently

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination ofdrug development consultancy, clinical trial design and execution. We offer a combination ofcarefully combined services offers our customers a complete service on all the stages of theirdrug development programs, from the early...

How previous experience with a notified body will help in the drug/medical device development consultancy.

As a medicinal expert at one of the leading notified bodies of the EU, I’ve been involved in the assessment of medicinal files of many different device-drug combination products. These are devices that include ancillary medicinal substances, in which the device has the primary mode...

Non-clinical consultancy

A small sized pharmaceutical company, who had already performed proof-of-concept studies with a small molecule drug candidate came to Venn Life Sciences with the aim to bring their product into clinic as soon as possible.

10 Features of the ATMPs development

There are several distinctive features that must be considered in the ATMP development: Have you experienced additional difficulties in your ATMP development? We would love to learn more about your development program and explore how we can impact your work. Let us facilitate your ATMP...

Scale-up and scale-down approaches in biologics

Appropriate scale-up/down is key for further larger production. Important is to focus to the right parameters that can help us to set the design for all experiments at lab scale.The common approach within the up-stream processing (USP) part in biologics is to increase the scale...

CMC regulatory team capabilities with Medical Devices

The CMC regulatory team has 20+ years’ experience supporting several pharma (small and large molecules) and medical device companies to ensure the continual manufacture and supply of high quality products to patients in licenced global markets.

« Previous 1 2 3 4 5 … 8 Next »